Under the JAVELIN Lung 100 study, the companies aim to assess the safety and efficacy of avelumab compared with platinum-based doublet chemotherapy, in patients with late-stage NSCLC who
Nucala is approved as an add-on maintenance treatment for patients aged 12 and older. It is administered once every four weeks by injection. The drug is a monoclonal
As per the terms of the licensing deal, Allergan will fund phase 3 development of tavilermide. Mimetogen will receive an upfront payment of $50m from Allergan. The deal
The company enrolled the first patients in the study of BI 1482694 (HM61713) in patients with non-small cell lung cancer (NSCLC) whose tumours test positive for the T790M
The approval is subject to Mylan’s divestiture of several products after the consummation of the offer. Mylan is offering $75 in cash and 2.3 ordinary shares for each
The companies have started a phase I clinical trial to evaluate GSK’s investigational GSK3174998 as monotherapy in combination with Merck’s Keytruda (pembrolizumab) in patients with tumors that have
The existing partnership is in the field of chronic obstructive pulmonary disease (COPD). Under the extended deal, the parties will set up a second team of scientists from
Each therapy will feature a mixture of synthetic messenger RNAs (mRNAs). BioNTech will receive $60m in upfront and near-term milestone payments. The company could also receive more than
The formulation for the spray includes three important ingredients which get absorbed quicker, penetrate deep to reach the source of pain and reduce inflammation. Nise D Spray will
Dyax develops plasma kallikrein (pKal) inhibitors for the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening disease that causes swelling. The deal gives Shire access to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.